Every 10-Q that Protara Therapeutics, Inc. (TARA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TARA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TARA filings page.
Protara Therapeutics, Inc. reported a larger loss as it continued funding multiple late‑stage development programs. For the six months ended June 30, 2026, net loss was $39.5 million compared with $26.9 million a year earlier, driven by higher research and development and personnel costs. Total operating expenses rose to $43.0 million, including $30.5 million in research and development and $12.4 million in general and administrative expenses.
Liquidity remains solid for a clinical‑stage company. As of June 30, 2026, Protara held $161.9 million in unrestricted cash, cash equivalents and marketable debt securities, total assets of $176.1 million, and stockholders’ equity of $161.3 million. Management believes these resources are sufficient to fund estimated needs for at least 12 months while advancing TARA‑002 in bladder cancer and lymphatic malformations and IV Choline Chloride in a Phase 3 trial for patients on parenteral support.
Protara Therapeutics reported a wider net loss for the three months ended March 31, 2026 as it accelerated investment in its pipeline. Net loss was $17.8 million versus $11.9 million a year earlier, driven by higher research and development spending of $13.6 million and general and administrative costs of $6.1 million.
The company ended the quarter with $177.4 million in unrestricted cash, cash equivalents and marketable debt securities and believes this will fund operations for at least 12 months. Protara advanced multiple programs, including TARA-002 for non-muscle invasive bladder cancer with promising complete response rates, TARA-002 for pediatric lymphatic malformations with interim clinical success in STARBORN-1, and initiated the registrational THRIVE-3 Phase 3 trial for IV Choline Chloride in long-term parenteral support patients.
Protara Therapeutics filed its quarterly report, showing a net loss of $13.3 million for the three months ended September 30, 2025 and $40.1 million for the nine-month period. Operating expenses rose to $14.8 million in the quarter, driven by research and development of $9.6 million and general and administrative of $5.2 million. Interest and investment income was $1.5 million in the quarter.
Liquidity remained solid with unrestricted cash, cash equivalents and marketable debt securities of $133.6 million as of September 30, 2025; management believes resources are sufficient for at least twelve months. Working capital was $125.7 million. Shares outstanding were 38,587,260 as of November 6, 2025.
Program updates: In NMIBC, interim ADVANCED-2 data (April 2025 cutoff) showed complete response rates in BCG‑Unresponsive patients of 100% at six months (5/5) and 67% at 12 months (2/3). An interim read from Cohort B (~25 six‑month evaluable patients) is planned for Q1 2026. IV Choline Chloride advanced toward THRIVE‑3 with EU‑CTR approval in July 2025 and first dosing targeted by year‑end 2025. In LMs, STARBORN‑1 early data included two complete responses; an interim update is expected in Q4 2025.
Protara Therapeutics is a clinical-stage biopharmaceutical company advancing TARA-002 (cell therapy) and IV Choline Chloride (intravenous choline) and has no product revenues. For the six months ended June 30, 2025 the company reported a net loss of $26.9 million versus $20.6 million in the prior year period, driven by higher research and development and general and administrative expenses. Cash and cash equivalents declined to $31.5 million while marketable debt securities increased after purchases, leaving $145.6 million in unrestricted cash and marketable securities and $115.3 million in working capital, which management states is sufficient for at least twelve months.
The company highlighted clinical progress: interim ADVANCED-2 data showed high complete response rates in small cohorts (BCG-Unresponsive 100% any-time CR 5/5; BCG-Naive 76% any-time CR 16/21) with mostly Grade 1 adverse events and no Grade 3+ treatment-related events. IV Choline Chloride received FDA Fast Track and orphan considerations and patents through 2041; Protara plans to initiate the THRIVE-3 registrational trial in Q3 2025 and obtained EU-CTR approval in July 2025. Recent financings include a December 2024 public offering (gross ~$100.1M, net ~$93.4M) and an April 2024 private placement (net ~$41.96M). The company notes it will need additional capital to fully execute its clinical plans.